OSR Holdings, Inc. (OSRH) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. OSR Holdings, Inc. is a global healthcare company formed via a business combination with OSR Holdings Co., Ltd. (Korea) on February 14, 2025. The company operates through four wholly-owned subsidiaries focusing on oral immunotherapies for cancer, design-augmented biologics for degenerative diseases, and neurovascular medical device distribution in Korea. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Sales | $627,747 | $822,996 | $2,524,536 | $2,615,051 |
| Gross Profit | $261,734 | $179,093 | $463,201 | $651,215 |
| Gross Margin | 41.7% | 21.8% | 18.3% | 24.9% |
| Operating Loss | $(3,803,465) | $(3,566,542) | $(11,950,469) | $(10,079,178) |
| Net Loss | $(3,194,874) | $(3,356,533) | $(19,812,886) | $(8,989,387) |
| Cash & Equivalents | $2,177,309 (as of Sept 30, 2025) | |||
| Total Debt (Short-term) | $4,329,856 (as of Sept 30, 2025) |
Note: Net loss includes significant non-cash items such as amortization of intangible assets ($7.0M YTD) and merger-related costs.
Material Changes vs. Prior Period
- Revenue & Margins: Q3 2025 revenue decreased 24% year-over-year due to a strategic shift in the RMC subsidiary from a purchase-and-resale model to a consignment-based model. However, this shift improved the Q3 gross margin to 41.7% from 21.8% in the prior year. YTD gross profit declined 29% due to a one-time inventory sell-back in Q2.
- Expenses: Selling, General, and Administrative (SG&A) expenses increased 16% YTD, driven by personnel costs, professional fees, and public company obligations following the February 2025 business combination.
- Other Expenses: Net other expenses surged YTD due to approximately $8.5 million in one-time merger-related costs and losses on the change in fair value of financial liabilities.
- Liquidity: Cash and cash equivalents increased significantly from $341,543 at year-end 2024 to $2,177,309 at Q3 2025, supported by financing activities including an Equity Line of Credit (ELOC) and warrant exercises.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D expenses to range from $2.5M to $3.0M per quarter starting in 2026, potentially rising to $5.0M-$6.0M per quarter. The company plans to utilize its ELOC (up to $78.9M available) and other financing instruments to fund operations.
- Nasdaq Compliance: The company received a deficiency notice on September 5, 2025, for failing to maintain a $1.00 minimum bid price. It has a grace period until March 4, 2026, to regain compliance.
- Legal Proceedings: Two active lawsuits are noted: a claim by Benjamin Securities, Inc. for $425,000 in brokerage fees, and a breach of contract complaint filed by Chardan Capital Markets, LLC regarding deferred underwriting commissions.
- Acquisitions: In October 2025, the company announced a definitive agreement to acquire Woori IO Co., Ltd., a medical device company specializing in noninvasive glucose monitoring.
Investor Verification Checklist
- Capital Adequacy: Verify the sufficiency of the $2.18M cash balance against the $11.95M YTD operating loss and upcoming R&D burn rate.
- Debt Structure: Review the terms of short-term borrowings ($4.3M total), including the $800k Duksung Co., Ltd. loan extended in October 2025 and the $1.11M convertible notes with White Lion Capital.
- Dilution Risk: Assess the potential dilution from the ELOC (up to $78.9M), outstanding warrants, and convertible notes.
- Listing Status: Monitor the company's progress in regaining Nasdaq compliance by the March 4, 2026 deadline.
- Legal Exposure: Track the status of the Chardan Capital Markets lawsuit regarding the $2.07M deferred underwriting commission.